Rationale and Design of a Multicenter, Phase 2 Clinical Trial to Investigate the
Efficacy of Traditional Chinese Medicine SaiLuoTong in Vascular Dementia.
Author(s): Liang J(1), Li F(2), Wei C(1), Song H(1), Wu L(1), Tang Y(1), Jia J(3).
Affiliation(s): Author information:
(1)Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing,
China.
(2)Department of Neurology, Fu Xing Hospital, Capital Medical University, Beijing,
China.
(3)Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing,
China. Electronic address: jiajp@vip.126.com.
Publication date & source: 2014, J Stroke Cerebrovasc Dis. ,
BACKGROUND: Vascular dementia (VaD) is the second most prevalent type of dementia
among the aged, for whom limited pharmacologic options are available so far.
SaiLuoTong capsule is a modern traditional Chinese medicine formula, which has
been demonstrated to improve cognition of VaD by the reports of animal
experiments and preliminary clinical trial. However, evaluation of this therapy
in randomized multicenter trials is needed. In this article, we present the
rationale and design of the SaiLuoTong in Vascular Dementia Study.
METHODS: This phase 2 clinical trial of SaiLuoTong among patients with
mild-to-moderate VaD is a 26-week, multicenter, randomized, double-blind,
placebo-controlled study with a subsequent 26-week, open-label extension. After a
4-week placebo run-in period, participants are centrally randomized (1:1:1) to 3
groups: group A receives SaiLuoTong 360 mg per day for 52 weeks; group B receives
SaiLuoTong 240 mg per day for 52 weeks; group C (the control group) are further
randomly assigned to 2 groups in a 1:1 ratio and receives placebo during the
double-blind phase, then SaiLuoTong 360 mg per day or SaiLuoTong 240 mg per day
during the extension phase. The primary outcome measures include the VaD
assessment scale cognitive subscale and the Alzheimer Disease Cooperative
Study-clinical global impression of change. Safety measures include body weight,
vital signs, electrocardiography, laboratory tests, and records of adverse
events. Assuming an attrition rate of 20%, at least 372 patients are required to
obtain a statistical power of 80%.
RESULTS: The first patient was enrolled into the study in April 2012 and the
completion of the study is expected in September 2014.
CONCLUSIONS: The rigorous methodology of the study will hopefully move forward
the scientific evaluation of traditional Chinese medicine in treatment of VaD.
The results of the present study will provide high-quality evidence on the effect
of SaiLuoTong in patients with VaD and has the potential to establish a novel
therapeutic approach for this disorder.
|
